AtlasXomics and EpiCypher announce partnership to commercialize spatial epigenomics assays
NEW HAVEN, Conn. and RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2024 /PRNewswire/ — AtlasXomics and EpiCypher announce their partnership to develop CUT&Tag kits and assay services for spatial epigenomics applications. These assays will be developed on AtlasXomics’ DBiT-seq platform using CUT&Tag reagents and antibodies from EpiCypher, expanding the spatial ‘omics toolbox to histone post translational modifications (PTMs), transcription factors, and other chromatin regulators.
